Second, along the same line, mining two independent datasets that contain lung cancer (GSE135222) or melanoma (GSE78220) patients treated with anti-PD1/PD-L1 immunotherapies, we observed that higher THBS2 expression was associated with poor response and short PFS/OS after immunotherapy (Figure 9B, C). The gene discussed is THBS2; the disease is melanoma.